Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Title Xponential Fitness Q4 Earnings Report Insights for Investors

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Fitness and app
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Xponential Fitness, a leading fitness company, unveiled its Q4 earnings on February 29, 2024, providing valuable insights for investors. Surprisingly, the company fell short of estimated earnings by a significant -47.0%, reporting an EPS of $0.08 compared to the anticipated $0.15. Despite this, revenue saw a notable increase of $18.93 million from the same period the previous year.

Reflecting on past performance, Xponential Fitness also missed EPS in the previous quarter by $0.04, resulting in a 7.000000000000001% decline in share price the following day. Here is a summary of the company’s performance in various quarters:
– Q3 2023: EPS Estimate 0.15, EPS Actual 0.11, Revenue Estimate 74.68M, Revenue Actual 80.44M
– Q2 2023: EPS Estimate 0.11, EPS Actual 0.07, Revenue Estimate 71.93M, Revenue Actual 77.34M
– Q1 2023: EPS Estimate 0.13, EPS Actual -0.02, Revenue Estimate 65.45M, Revenue Actual 70.69M
– Q4 2022: EPS Estimate 0.10, EPS Actual 0.11, Revenue Estimate 66.74M, Revenue Actual 71.27M.

Investors seeking more in-depth financial information and updates on Xponential Fitness’s earnings releases and performance can explore their investor relations website.

XPOF Stock Price Update: February 29, 2024 – Is the Upward Momentum Sustainable?

On February 29, 2024, XPOF stock closed at $10.08, marking a $0.34 increase from the previous market close, representing a 3.49% rise in the stock price. In after-hours trading, the stock continued to climb, rising a further $0.33. Despite this positive movement, XPOF is currently trading near the bottom of its 52-week range and below its 200-day simple moving average, suggesting recent challenges. Investors may be watching XPOF to see if this upward momentum can be sustained. Conducting research before making investment decisions is important, as market conditions can change rapidly.

XPOF Stock Performance Analysis: Revenue Growth, Net Income Decline, and EPS Fluctuation – February 29, 2024

XPOF stock had a mixed performance on February 29, 2024, as the company reported its financial results for the past year and the third quarter. According to data from CNN Money, XPOF’s total revenue stood at $244.95 million for the past year, representing a 57.95% increase compared to the previous year. However, the total revenue for the third quarter was $80.44 million, showing a 4.0% increase compared to the previous quarter. XPOF’s net income for the past year was $22.16 million, which was a 17.86% decrease compared to the previous year. The net income for the third quarter was -$20.16 million, indicating a significant decrease of 632.74% compared to the previous quarter. In terms of earnings per share (EPS), XPOF reported a figure of -$0.87 for the past year, which was a 67.36% increase compared to the previous year. However, the EPS for the third quarter was -$0.50, showing a decrease of 143.91% compared to the previous quarter. Overall, XPOF’s stock performance on February 29, 2024, reflects a mixed picture with revenue showing strong growth but net income and EPS experiencing significant declines. Investors may need to closely monitor the company’s financial performance and outlook to make informed decisions about their investment in XPOF stock.

Tags: XPOF
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Capitalization

Analyzing Organogenesis Holdings Incs Q4 Earnings Performance

Finance_Accounting (2)

Elastic Corporations Q3 Financial Report Surprising Stock Drop Despite Exceeding Expectations

Biotechnology Stock Bull Market

Organogenesis Holdings Inc Reports Decline in Net Revenue for Q4 2023 Focuses on Growth Strategies for 2024

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com